The power of composite tests to track Alzheimer’s disease progression

Hearing loss and dementia

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

Best outcome measures for Alzheimer’s disease follow-up in the clinic

Streamlining dementia diagnosis with digital biomarkers

Trends in the use of surrogate biomarkers during clinical trials

TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab

Digital markers detect changes in neurocognitive performance in those with vs without hearing loss

Safety results of the Phase III gantenerumab GRADUATE I and II studies

Futility analysis in clinical trials: practical and ethical considerations

Research needs: determining reliability and robustness of plasma markers in Alzheimer’s disease

Exploring the potential role of amyloid deposition in the gut in Alzheimer’s disease

Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310

Facilitation of dementia diagnosis across the world

Decreased kidney function associated with increased plasma p-tau levels

Blood biomarkers for the differential diagnosis of Alzheimer’s disease in clinical practice